Ligand gated receptor interactions: A key to the power of neuronal networks

Neff, Robert A.; Kambara, Kumiko; Bertrand, Daniel

doi:10.1016/j.bcp.2021.114653

Cited by 4 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is imperative to explore a novel taxonomy to stratify stage II/III CRC patients well and determine who may truly demand or can omit ACT. Serving as the instrumental basis for the communication of cells with neighboring cells and the whole organism, LRIs exert widely divergent implications on CRC in many dimensions from the viewpoint of intercellular crosstalk 16,27,33 . Our study deciphered the heterogeneity of stage II/III CRC from the abnormal crosstalk of ligand-receptor gene pairs and proposed a promising subtyping scheme based on perturbations in LRIs.…”

Section: Discussionmentioning

confidence: 99%

“…Acting as a nexus in intercellular communication, ligand-receptor interactions (LRIs) are essential to most dynamic biological processes (including proliferation, apoptosis, motility, etc.). LRIs constitute an immensely complex network of interacting molecules via various cellular signaling pathways 16,33 . The ligand-receptor network regulates homeostasis and equilibrium in cells, mirrors the holistic and realistic nature of diverse cell-cell communications, and refracts the macroscopic state in a whole biological system or tissue 23,24,43 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perturbations in the ligand-receptor interactions unravel novel heterogeneous subtypes of stage II/III colorectal cancer

Han

Xu²,

Chen³

et al. 2023

Preprint

View full text Add to dashboard Cite

Approximately 10%-15% of stage II and 25%-30% of stage III colorectal cancer (CRC) patients experience recurrence within five years after surgery, while existing taxonomies are inadequate for daily clinical application. Therefore, a more reliable classification approach with higher accuracy and prognostic potential is urgently required to stratify stage II/III CRC and identify potential patients who will benefit from postoperative adjuvant therapy. Alternatively, interactions of ligand-receptor pairs point to an emerging direction in tumor signaling with far-reaching implications for CRC, while their impact on tumor subtyping has not been elucidated. Herein, 304 normal samples, 1,386 stage II/III CRC patients, and 2,557 ligand-receptor pairs were retrospectively retrieved. Grounded on perturbations in ligand-receptor interactions, four well-characterized and robust ligand-receptor-driven subtypes (LRDS1-4) were established in the discovery cohort and validated in meta-GEO cohort comprising nine independent cohorts. Specifically, LRDS1 was characterized by an immune-cold phenotype, with cell proliferation and differentiation-related functions and higher tumor purity; LRDS2 was endowed with matrix activation-related pathways and sensitive to fluorouracil-based chemotherapy; LRDS3 was distinguished by elevated metabolic activities and frequent 13q12.2 amplification; LRDS4 was an immune-hot subtype, driven by mutations, and exhibiting dismal prognosis with MEIS2 as the prognostic feature gene. Overall, our study developed four heterogeneous LRDS and shed novel insights into the implications of intercellular communication on stage II/III CRC from a ligand-receptor interactome perspective.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Perturbations in the ligand-receptor interactions unravel novel heterogeneous subtypes of stage II/III colorectal cancer

Han

Xu²,

Chen³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Serving as the instrumental basis for the communication of cells with neighboring cells and the whole organism, LRIs exert widely divergent implications on CRC in many dimensions from the viewpoint of intercellular crosstalk. 10,11,16 Our study deciphered the heterogeneity of stage II/ III CRC from the abnormal crosstalk of ligand−receptor gene pairs, proposing a promising subtyping scheme based on perturbations in LRIs and unraveling MEIS2 as a key factor in the aggressive progression and prognosis in stage II/III CRC.…”

Section: Discussionmentioning

confidence: 99%

“…Acting as a nexus in intercellular communication, ligand–receptor interactions (LRIs) are essential to most dynamic biological processes (including proliferation, apoptosis, motility, etc.). LRIs constitute an immensely complex network of interacting molecules via various cellular signaling pathways. , The ligand–receptor network regulates homeostasis and equilibrium in cells, mirrors the holistic and realistic nature of diverse cell–cell communications, and refracts the macroscopic state in a whole biological system or tissue. – Covering multiple cells in the ligand–receptor network, perturbations in LRIs cast a crucial influence on mechanisms of tumorigenesis, tumor progression, immune landscape, treatment resistance, and so forth. , More specifically, perturbations in PD-1 and PD-L1 hinder the activation and proliferation of CD8+ T cells in tumor samples . Crosstalk of interactions between decoy receptor and tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL ) may serve a critical role in the resistance to TRAIL -based therapies for CRC .…”

Section: Introductionmentioning

confidence: 99%

“…LRIs constitute an immensely complex network of interacting molecules via various cellular signaling pathways. 10,11 The ligand−receptor network regulates homeostasis and equilibrium in cells, mirrors the holistic and realistic nature of diverse cell−cell communications, and refracts the macroscopic state in a whole biological system or tissue. 12 of tumorigenesis, tumor progression, immune landscape, treatment resistance, and so forth.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cellular Ligand–Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer

Xu,

Chen,

et al. 2023

J. Proteome Res.

View full text Add to dashboard Cite

Approximately 10−15% of stage II and 25−30% of stage III colorectal cancer (CRC) patients experience recurrence within 5 years after surgery, and existing taxonomies are insufficient to meet the needs of clinical precision treatment. Thus, robust biomarkers and precise management were urgently required to stratify stage II and III CRC and identify potential patients who will benefit from postoperative adjuvant therapy. Alongside, interactions of ligand−receptor pairs point to an emerging direction in tumor signaling with far-reaching implications for CRC, while their impact on tumor subtyping has not been elucidated. Herein, based on multiple large-sample multicenter cohorts and perturbations of the ligand−receptor interaction network, four well-characterized ligand−receptor-driven subtypes (LRDS) were established and further validated. These molecular taxonomies perform with unique heterogeneity in terms of molecular characteristics, immune and mutational landscapes, and clinical features. Specifically, MEIS2, a key LRDS4 factor, performs significant associations with proliferation, invasion, migration, and dismal prognosis of stage II/III CRC, revealing promising directions for prognostic assessment and individualized treatment of CRC patients. Overall, our study sheds novel insights into the implications of intercellular communication on stage II/III CRC from a ligand−receptor interactome perspective and revealed MEIS2 as a key factor in the aggressive progression and prognosis for stage II/III CRC.

show abstract

Nalbuphine-6-glucuronide is a potent analgesic with superior safety profiles by altering binding affinity and selectivity for mu-/kappa-opioid receptors

Chen,

Lai,

Huang

et al. 2024

Life Sciences

View full text Add to dashboard Cite

Ligand gated receptor interactions: A key to the power of neuronal networks

Cited by 4 publications

References 61 publications

Perturbations in the ligand-receptor interactions unravel novel heterogeneous subtypes of stage II/III colorectal cancer

Perturbations in the ligand-receptor interactions unravel novel heterogeneous subtypes of stage II/III colorectal cancer

Cellular Ligand–Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer

Nalbuphine-6-glucuronide is a potent analgesic with superior safety profiles by altering binding affinity and selectivity for mu-/kappa-opioid receptors

Contact Info

Product

Resources

About